calanderBy Prof. A.G.(Onno) Holleboomcalander16 March 2022
NAFLD / NASH as a metabolic disease: improving patients outcomes

Prof. A.G.(Onno) Holleboom, Netherlands, discusses non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) as a metabolic disease and reviews management strategies in order to improve patients outcomes. He discusses the spectrum of NAFLD, where he presents a snapshot of the relative damages and repairs which focus on the NAFLD field in 2022. He then discusses the hepatic component metabolic syndrome (MetSy) and the mechanisms and pharmacological developments on NAFLD / NASH. For the clinicians he presents various statistics that summarise NAFLD / NASH as an ever more prevalent and severe liver disease.